Two pivotal phase III trials, FIDELIO-DKD and FIGARO-DKD, demonstrated that finerenone, when added to the maximum tolerated dose of a renin–angiotensin–aldosterone system (RAAS) inhibitor, significantly reduced proteinuria, cardiovascular events, and renal disease progression [158]. This evidence concerns the gene REN and kidney disorder.